Skip to main content
Shandong Sanyuan Biotechnology Co.,Ltd logo

Shandong Sanyuan Biotechnology Co.,Ltd — Investor Relations & Filings

Ticker · 301206 ISIN · CNE100005774 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 611 across all filing types
Latest filing 2026-06-05 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301206

About Shandong Sanyuan Biotechnology Co.,Ltd

https://www.sanyuanbz.com

Shandong Sanyuan Biotechnology Co.,Ltd. specializes in the research, development, production, and sale of functional sugar substitutes, with a primary focus on erythritol. Utilizing advanced microbial fermentation technology, the company has established itself as a leading global manufacturer of erythritol, providing high-quality, zero-calorie, and non-GMO sweetening solutions. Its product portfolio includes pure erythritol and various compound sweeteners blended with ingredients such as stevia and monk fruit to meet diverse formulation needs. The company serves a broad international clientele within the food, beverage, and pharmaceutical sectors, emphasizing health-oriented alternatives to traditional sugar. By leveraging large-scale production capabilities and rigorous quality control standards, it supports the global shift toward reduced-sugar and calorie-conscious consumer products.

Recent filings

Filing Released Lang Actions
关于2026年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告
Regulatory Filings Classification · 85% confidence The document is a self-inspection report (“自查报告”) regarding insider personnel and incentive participants trading the company’s shares around a restricted stock incentive plan. It contains no financial statements or summary of results, nor is it announcing a new report or detailing an AGM presentation. It is a compliance disclosure falling into the general regulatory filings category rather than a specific financial report or transaction notice. Therefore, it should be classified as Regulatory Filings (RNS).
2026-06-05 Chinese
董事会薪酬与考核委员会关于2026年限制性股票激励计划激励对象名单的核查意见及公示情况的说明
Share Issue/Capital Change Classification · 80% confidence The document is a public announcement by the board’s remuneration & assessment committee concerning the verification of the 2026 restricted stock incentive plan recipients list and details of the internal public notice. It deals with the company’s share‐based compensation plan and involves the future issuance of restricted shares under the incentive plan. This falls under announcements related to share issuance/capital changes rather than an earnings report, management change, or regulatory certification.
2026-06-05 Chinese
关于年产2万吨阿洛酮糖项目投产的公告
Regulatory Filings Classification · 85% confidence The document is an exchange announcement by Shandong Sanyuan Bio-technology Co., Ltd. reporting the commissioning and start of production of its 20,000-ton allulose project. It does not contain financial statements or earnings data, nor does it announce a board change, financing, dividends, or legal proceedings. It is not a report publication notice but the actual announcement itself. This type of operational/project update falls under the general Regulatory Filings category (RNS) as a fallback for miscellaneous corporate announcements.
2026-06-03 Chinese
关于继续使用暂时闲置超募资金进行现金管理的进展公告
Capital/Financing Update Classification · 79% confidence The document is a formal announcement by Shandong Sanyuan Biotechnology Co., Ltd. detailing the progress of using temporarily idle over‐subscribed (超募) funds for cash management. It includes transaction details, board resolutions, risk measures, and related disclosures on investment products purchased and redeemed. This is not an earnings release, management discussion, or regulatory attestation, but specifically updates on the use of financing proceeds. Therefore it falls under Capital/Financing Update (CAP).
2026-06-01 Chinese
董事会薪酬与考核委员会关于公司2026年限制性股票激励计划的核查意见
Share Issue/Capital Change Classification · 70% confidence The document is an opinion (“核查意见”) issued by the company’s Board Compensation and Assessment Committee regarding the 2026 restricted stock incentive plan. It focuses on compliance with corporate law, securities law, stock exchange rules, and the company’s articles in order to implement a stock-based incentive—which is effectively a planned share issuance arrangement. This is not a financial report, audit, dividend notice, or regulatory certification, nor is it a mere announcement of availability. Instead, it concerns the structure and legal compliance of a share issuance/incentive scheme. Therefore, the most appropriate category is Share Issue/Capital Change (SHA).
2026-05-25 Chinese
2026年限制性股票激励计划（草案）摘要
Share Issue/Capital Change Classification · 80% confidence The document is the detailed ‘2026 Restricted Stock Incentive Plan (Draft) Summary’ for Shandong Sanyuan Biology Co., outlining the grant of 2.3257 million new A-shares to directors, senior management, and core staff under a share-based compensation scheme. It is an announcement of an impending issuance of restricted shares (i.e., a capital change via new share issue) rather than a standalone annual or interim report, proxy statement, or earnings release. Therefore, it best fits the Share Issue/Capital Change category.
2026-05-25 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.